0 CHECKOUT

PRODUCT FILTERS

REGION

83
50
48
43
29

COUNTRY

23
19
16
13
1

CATEGORIES

  • 127
  • 27
  • 18
  • 17
  • 16
  • 10
  • 9
  • 8
  • 8
  • 7
  • 4
  • 4
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
SHOW ALL

PRICE

43
152
169
262

PUBLISHED

1
9
74
262

PRODUCT TYPE

243
14
3
2

Search for: "Analysis of the Anticoagulant Market"

Rodenticides Market by Type, by End User & by Geography - Global Trends & Forecasts to 2019

Rodenticides Market by Type (Anticoagulants, Non-Anticoagulants, and Others), by End User (Agricultural Field, Warehouses, Pest Control Companies, Urban Centers, and Others) & by Geography - Global...

Published:  July 2014
Price:  From

Anticoagulants - Global Strategic Business Report

This report analyzes the worldwide markets for Anticoagulants in Millions of US$ by the following Product Segments: Oral Anticoagulants, and Injectable Anticoagulants (Unfractionated Heparin, and Low...

Published:  October 2012
Price:  From

Rodenticides Market: By Type; By Geography - Forecast (2015-2020)

Rodenticides are used for pest control management, where it kill rodents, including squirrels, woodchucks, chipmunks and other animals. These rodents require control as they can damage crops, transmit...

Published:  August 2015
Price:  From

New Oral Anticoagulants Markets

Anticoagulants decrease the ability of the blood to create harmful blood clots that can ultimately leading to a heart attack or stroke Although sometimes referred to as blood thinners, they do not actually...

Published:  March 2013
Price:  From

Edoxaban - Potential Game Changer in Oral Anticoagulant Market

Edoxaban - Potential Game changer in oral anticoagulant market Stroke Prevention in Atrial Fibrillation represents the largest opportunity for the new generation oral anticoagulants, besides a very...

Published:  September 2012
Price:  From

Atrial Fibrillation Global Physician Survey - 2014

The authors have conducted an extensive global survey of leading physicians in atrial fibrillation to provide treatment insights and practice patterns Physicians were selected based on their relevant...

Published:  March 2014
Price: 

Coagulation Self-testing to 2020

The size and future potential of the coagulation self-testing market has been evolving over the past 24 months as two competing forces work to inject uncertainty into future demand. Demographic and...

Published:  June 2015
Price: 

Autoinjectors to 2022

Syringes that can be prefilled on standard fill-and-finish lines have had a dramatic effect on the way injectable drugs are developed, prescribed and administered. This impact has been accelerated by...

Published:  January 2015
Price:  From

Thought Leader Insight & Analysis Report: Anticoagulants Q2 2010

This Cardiovascular Thought Leader Panel reviews the most important anticoagulant data presented at ACC 2010 with six international Thought Leaders who have a stake in anticoagulation therapy The discussions...

Published:  May 2010
Price: 

Drug Injection Devices to 2022

The correlation between chronic conditions and the benefits of patient self-administration continues to influence therapeutic product decisions, managed care initiatives and regulatory actions. Drug...

Published:  May 2015
Price: 

Autoinjectors to 2024

Syringes that can be prefilled on standard fill-and-finish lines have had a dramatic effect on the way injectable drugs are developed, prescribed and administered. This impact has been accelerated by...

Published:  January 2016
Price:  From

Generic Drug Opportunity Assessment - Apixaban (Eliquis)

The branded drug Eliquis (apixaban) represents an attractive opportunity for generic drug companies that utilize the provisions under Section 505(j)(2)(A)(vii)(IV) as part of their ANDA-filing strategy...

Published:  January 2014
Price:  From

Anticoagulants in Stroke Prevention in Atrial Fibrillation (SPAF): Novel Oral Anticoagulants with Superior Safety Profile will Drive the Market

Anticoagulants in Stroke Prevention in Atrial Fibrillation (SPAF): Novel Oral Anticoagulants with Superior Safety Profile will Drive the Market Summary Our report, “Anticoagulants in Stroke Prevention...

Published:  November 2010
Price:  From

Self-injectable Specialty Drugs to 2022

Increases in life expectancy are expected to result in a growing number of patients diagnosed with chronic conditions. To counteract the financial and logistical implications of this trend, pressure...

Published:  September 2015
Price: 

Prefilled Syringes to 2022

The administration of therapeutic drugs via injection is an indispensable delivery method for numerous drugs critical to patient health and well-being. Now this segment is evolving in response to changing...

Published:  January 2015
Price:  From

Injectable Drug Delivery Global Market Analysis - Forecast (2014-2020)

This analysis is one of the most accurate studies performed using the combinational analytical tools. The report contains up to date financial data derived from varied research sources to present unique...

Published:  July 2015
Price:  From

US Market for Hemostasis Devices - 2016 (Forecasted to 2022)

This segment includes only the analyzers and reagents used in core labs of hospitals and in independent commercial labs, without taking into consideration the point-of-care (POC) equipment. The U.S....

Published:  October 2015
Price:  From

Hypertrophic Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast, 2015 - 2023

This report on the hypertrophic cardiomyopathy therapeutics market studies the current and future prospects of the global market. Hypertrophic cardiomyopathy occurs if heart muscle cells enlarge and...

Published:  November 2015
Price:  From

FDA Approves Xarelto (Rivaroxaban) - The First New Oral Anticoagulant Approved to Prevent VTE in Joint Replacement Surgeries in the US

FDA Approves Xarelto (Rivaroxaban) - The First New Oral Anticoagulant Approved to Prevent VTE in Joint Replacement Surgeries in the US Summary GlobalData’s report “FDA Approves Xarelto (Rivaroxaban)...

Published:  July 2011
Price:  From

Cardiovascular Disease: Recent Drug Advances and Impending Risks

There are nearly 300 medicines in clinical development to treat cardiovascular disease This new research report examines in detail the key areas of the cardiovascular (CV) market, gathering inside opinion...

Published:  June 2013
Price: 
Loading Indicator

Our Clients

  • Hewlett-Packard Company
  • Microsoft Corporation
  • Philips N.V.
  • SONY Corporation
  • Cypress Semiconductor Corporation
  • Panasonic Corporation